## ASSIGNMENT RECORDATION FORM COVER SHEET Patents Only

	Date: August 17, 2012			
To: Commissioner for Patents:	Attorney Docket No. 9336-50DS			
Please record the attached original documents or copy thereof.				
1. Name of conveying party(ies):	2. Name and address of receiving party(ies):  Oriel Therapeutics, Inc. 630 Davis Drive, Suite 120 Durham, North Carolina 27713			
[1.] Insight Product Development LLC				
Additional name(s) of conveying party(ies) attached? Yes x No	4			
3. Nature of conveyance:				
x Assignment Merger Security Agreement Change of Name Other Execution Date: [1.] July 26, 2012	Additional name(s) & address(es) attached? Yes No			
4. Design Application Serial No. 29,420,366, filed May 8, 2012  If this document is being filed together with a new application, the execution date of the application is:  Additional numbers attached?Yes _xNo				
5. Name and address of party to whom correspondence	6. Total number of applications and patents involved: 1			
concerning document should be mailed:  Julie H. Richardson Myers Bigel Sibley & Sajovec P. O. Box 37428 Raleigh NC 27627	7. Total fee (37 CFR 3.41) \$40.00  Enclosed  X Authorized to be charged to deposit account  8. Deposit account number: 50-0220			
DO NOT USE THIS SPACE				
of the original document.  Tulie H. Richardson	August 17, 2012  ignature  d document: 4			
CERTIFICATION OF	FACSIMILE TRANSMISSION ER 37 CFR § 1.8 e transmitted to the U.S. Patent and Trademark Office via Assignment Branch			
/				

PATENT REEL: 028808 FRAME: 0665

Attorney Dkt No. 9336-50DS

## ASSIGNMENT

THIS ASSIGNMENT, made by Insight Product Development LLC, a company registered in Illinois having a principal place of business at 4660 N. Ravenswood Ave., Chicago, Illinois 60640, hereinafter referred to as Assignor;

WITNESSETH: That,

WHEREAS, the above-named corporation, through its employee, Andrew Valentine, is one of the co-owners of the entire right, title, and interest in and to an ornamental design for **INHALER**, for which Design Patent Application Serial Number 29/420,366 was filed in the United States Patent and Trademark Office on May 8, 2012; and

WHEREAS, Oriel Therapeutics, Inc., a Delaware corporation having a principal place of business at 630 Davis Drive, Suite 120, Durham, North Carolina, 27713, hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in and to said design as described in said design application, and in and to any and all Letters Patent or other form of design protection which shall be granted therefor in the United States of America and all foreign countries;

NOW, THEREFORE, To All Whom It May Concern, be it known that for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the above Assignor has sold and by these presents does hereby sell, assign, transfer, and convey unto the said Assignee, its successors and assigns, the entire right, title, and interest in and to the said design and design application, and in and to any and all continuations, continuations-in-part, or divisions thereof, and in and to any and all Letters Patent of the United States of America and all foreign countries or reissues or other forms of protection thereof which may be granted therefor or thereon, for the full end of the term for which said Letters Patent may be granted along with any term extensions thereon or therefor, together with the right to claim the priority of said design application in all foreign countries in accordance with the International Convention, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made.

The Assignor hereby requests that said Letters Patent be issued in accordance with this assignment.

Page 1 of 3

Attorney Dkt No. 9336-50DS

The Assignor further covenants and agrees that, at the time of the execution and delivery of these presents, it possesses its full title to the design and patent application thereon as earlier identified, and that it has the unencumbered right and authority to make this assignment.

The Assignor further covenants and agrees to promptly communicate to said Assignce or its representatives any facts known to the Assignor relating to said design, to testify in any interference or legal proceedings involving said design, to execute any additional papers which may be requested to confirm the right of the Assignee, its representatives, successors, or assigns to secure patent or similar protection for the said design in all countries and to vest in the Assignee complete title to the said design and Letters Patent, without further compensation, but at the expense of said Assignee, its successors, assigns, and other legal representatives; and the Assignor hereby instructs, and further covenants and agrees to bind its legal representatives and assigns, to do same, without further compensation, but at the expense of said Assignee or its representatives.

I	V WITNESS WHI	EREOF, the Assignor has ca	used this assignment	to be executed	
this	day of	, 2012. The und	2. The undersigned warrants and represents that		
he/she ha	as the authority to	sign this Assignment on bel	alf of the Assignor, l	Insight Product	
Develop	ment LLC.	By:	<u>&gt;</u>	_(SEAL)	
	Witness	Title: Photon	7/26/1Z Date	_	
	Witness	3	Date	•	

Attorney Dkt No. 9336-50DS

IN WITNESS WHEREOF, the Assignee, by signature below, hereby confirms and accepts receipt of this assignment. The undersigned warrants and represents that he/she has the authority to significant on behalf of the Assignee, Oriel Therapeutics, Inc.

15 August 2012 15 August 2012